TCGA-MZ-A7D7-01A-21R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.550
- FATTY_ACID_METABOLISM+0.370
- MYC_TARGETS_V1+0.360
- PANCREAS_BETA_CELLS+0.310
- PEROXISOME+0.250
- BILE_ACID_METABOLISM+0.230
- DNA_REPAIR+0.220
- ADIPOGENESIS+0.210
- SPERMATOGENESIS+0.200
- PROTEIN_SECRETION+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.400
- MITOTIC_SPINDLE-0.400
- MYOGENESIS-0.390
- NOTCH_SIGNALING-0.390
- APICAL_JUNCTION-0.370
- ALLOGRAFT_REJECTION-0.350
- HEDGEHOG_SIGNALING-0.340
- ESTROGEN_RESPONSE_EARLY-0.320
- UV_RESPONSE_DN-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG42 | — | — | 0.866 |
| 2 | TCGA-37-4135-01A-01R-1100-07 | — | cohortA1 | 0.865 |
| 3 | TCGA-64-1678-01A-01R-0946-07 | — | cohortA3 | 0.851 |
| 4 | SRR6013568 | — | cohortA2 | 0.849 |
| 5 | SRR8518428 | — | F | 0.843 |
| 6 | SRR1350220 | GTEX | — | 0.842 |
| 7 | SRR8518448 | — | C | 0.838 |
| 8 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.832 |
| 9 | AUR-AFKF-TTM1-A-1-1-R-A742-41 | — | C | 0.828 |
| 10 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.070 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |